Menopause is emerging as a major, overlooked factor in brain health, yet science still knows surprisingly little about how the menopausal transition affects the nervous system. A new roadmap published in Nature Reviews Neurology argues that this gap is no longer acceptable, particularly for women who already live with neurological diseases. The authors, Rhonda Bove and Rachael Dobson, call for a research revolution capable of treating menopause not only as a reproductive event, but also as a biological and sociocultural process with consequences for the brain.
The menopausal transition, commonly known as perimenopause, is a period of substantial hormonal fluctuation that precedes the permanent end of menstruation. Although the process is often discussed in terms of hot flashes, sleep disruption and reproductive ageing, its effects may extend to cognition, mood, sensory processing and the course of neurological disease. During this stage, ovarian hormone levels do not simply decline in a smooth line; they can vary considerably before reaching the lower, relatively stable levels characteristic of postmenopause. The brain must therefore adapt to a changing biochemical environment over several years.
That adjustment may help explain why cognitive concerns are so common during the transition. Approximately two thirds of women report problems such as forgetfulness, difficulty concentrating or a sense of mental “fog”. These experiences are frequently dismissed as stress, ageing or poor sleep, but the roadmap emphasizes that they deserve rigorous scientific investigation. Cognitive performance is influenced by many interacting factors, including hormonal changes, sleep quality, mood, vascular health and social pressures. Separating these influences will require studies that measure them simultaneously rather than attributing every symptom to a single cause.
The biological mechanisms remain incompletely understood. Sex hormones such as oestrogen interact with receptors distributed throughout the brain and can influence neuronal communication, energy use, plasticity and inflammatory signalling. When hormone levels fluctuate or decline, these systems may respond differently, potentially altering how the brain handles metabolic demands and environmental stress. Such mechanisms are plausible pathways, not yet universal explanations for individual symptoms. The authors stress that much more work is needed to determine which changes are temporary adaptations and which might contribute to lasting neurological vulnerability.
The problem becomes more urgent when menopause occurs in a person with an established neurological condition. Existing diseases may change during perimenopause or after menstruation permanently stops, yet the available evidence is too limited to explain who is most at risk or why. Symptoms of neurological disease may overlap with menopausal symptoms, making clinical assessment difficult. Fatigue, sleep disturbance, mood changes and cognitive impairment can arise from several causes at once. Without sex-specific research and carefully designed clinical tools, physicians may struggle to distinguish a change in disease activity from a new menopause-related symptom—or recognize when both are occurring together.
The roadmap also highlights the importance of understanding the postmenopausal phase, when the brain encounters a different hormonal baseline. Researchers need to examine whether this transition influences disease course, treatment response and long-term disability in women with neurological disorders. Such research should include detailed information about age at menopause, the duration of perimenopause, hormonal exposures, reproductive history, medication use and social circumstances. These variables could affect neurological outcomes, but many existing studies have not collected them systematically.
Earlier menopause represents another unresolved warning signal. Studies have associated an earlier age at menopause with a higher risk of later cognitive decline, but association does not establish causation. Earlier menopause may reflect genetic factors, medical treatment, surgery, chronic illness or broader differences in vascular and social health. It is also unclear whether the timing of menopause itself drives future neurological risk, whether the duration of hormone exposure matters, or whether common underlying factors explain both early menopause and cognitive change. Long-term studies beginning before the menopausal transition will be essential for answering these questions.
The authors argue that historical and scientific obstacles have slowed progress. Women’s health has often been compartmentalized, with reproductive medicine, neurology, psychiatry and ageing research operating in separate fields. Menopause has also been treated as a narrow stage of reproductive biology rather than a life-course event relevant to multiple organ systems. Meanwhile, women with neurological conditions have frequently been excluded from research or studied without detailed consideration of hormonal status. This has produced datasets that are too small, too fragmented or too inconsistent to reveal meaningful patterns.
A stronger research agenda would combine population studies, laboratory science and clinical trials. Scientists could track neurological symptoms and cognitive performance across the entire transition, while using hormonal measurements, brain imaging and biological markers to identify underlying mechanisms. Clinical trials should test whether management strategies need to be adapted according to menopausal stage and neurological diagnosis, rather than assuming that one approach works for everyone. Researchers must also account for ethnicity, socioeconomic conditions, access to healthcare and cultural attitudes, because menopause is shaped by both biology and society.
The central message of the roadmap is not that menopause inevitably damages the brain, but that its neurological significance has been underestimated. For millions of women, the transition may intersect with existing disease, emerging cognitive symptoms and long-term health risks at the same time. Filling this knowledge gap could improve diagnosis, prevent unnecessary suffering and lead to more precise, sex-specific care. Until menopause is routinely integrated into neurological research and clinical decision-making, one of the most influential biological transitions in women’s lives will remain scientifically underexplored.
Subject of Research: Menopause, brain health and neurological disorders
Article Title: Menopause and neurological disorders: a roadmap for research
Article References: Bove, R., Dobson, R. Menopause and neurological disorders: a roadmap for research. Nature Reviews Neurology (2026). https://doi.org/10.1038/s41582-026-01244-5
Image Credits: AI Generated
DOI: 10.1038/s41582-026-01244-5
Keywords: menopause, perimenopause, brain health, neurological disorders, cognitive decline, women’s health, neurobiology, sex-specific medicine, ageing, neuroscience
Tags: biological and sociocultural aspects of menopausecognition and mood changes in menopausehormonal fluctuations during perimenopausehormonal influence on sensory processinghormonal therapy and neurological disease riskhormonal transition and neuroplasticitymenopause and brain healthmenopause and sleep disturbancesmenopause-related neurocognitive declinemenopause’s impact on neurological disordersneuroendocrine regulation in womenresearch priorities in women’s neurological health
